Torrent Pharmaceuticals
Torrent Pharma delivered a strong Q3 FY26 with 18% revenue growth to ₹3,333 crore and 19% EBITDA growth to ₹1,088 crore, driven by double-digit expansion in India (+14%) and Brazil (+27% reported, +10% constant curren...
Torrent Pharmaceuticals vs Fortis Healthcare Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Fortis Healthcare
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin r...
Result Snapshot
Revenue₹3,333 Cr₹2,265 Cr
PAT₹635 Cr₹197 Cr
EBITDA Margin32.9%22.3%
Sentimentbullishbullish
Key Quotes
Our two largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%.
Our business performance in Q3 has been good considering the seasonal impact of festivals in some of our key geographies.